Jonathan Ledermann, B.Sc., MD, FRCP on Gynecological Cancer at the European Cancer Congress 2013

  • The ICON 6 trial: Data of anti-VEGF drug cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer
  • Data of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib or placebo (Monk B)
  • Vintafolide therapy (Neumann RW)

For more information:
[1] Cediranib Improves Survival in Women with Recurrent Ovarian Cancer [Article]

Abstracts: General

  • Abstract: # 10. Author(s) and title: Ledermann JA, Perren TJ, Raja FA, Embleton A, Rustin GJS, Jayson G, Kaye SB, Swart AM, Vaughan M, Hirte H. LATE BREAKING ABSTRACT: Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial [Abstract Link]
  • Abstract: # 41. Author(s) and title: Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Navale L, Warner DJ, Oza AM. LATE BREAKING ABSTRACT: A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1 [Abstract Link]

This interview is produced in collaboration with

 

Copyright © 2012 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco'Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+